Table 1 Baseline clinicopathological characteristics of esophageal squamous cell carcinoma patients
Characteristics | Gender | Muscle-Adipose Index | ||||
|---|---|---|---|---|---|---|
Female (N = 100) | Male (N = 204) | P | Unbalance (N = 173) | Balance (N = 131) | P | |
Age (years) | Â | Â | 0.153 | Â | Â | 0.623 |
 < 65 | 56 (56%) | 133 (65.2%) |  | 105 (60.7%) | 84 (64.1%) |  |
 ≥ 65 | 44 (44%) | 71 (34.8%) |  | 68 (39.3%) | 47 (35.9%) |  |
BMI | Â | Â | 0.206 | Â | Â | 0.669 |
 Mean ± SD | 23.477 ± 3.567 | 22.929 ± 3.534 |  | 23.185 ± 3.658 | 23.009 ± 3.409 |  |
Sum of adipose tissue (cm2/m2) |  |  |  < 0.001 |  |  | 0.514 |
 Mean ± SD | 63.798 ± 9.822 | 55.497 ± 6.498 |  | 58.497 ± 9.837 | 57.872 ± 6.834 |  |
Sum of muscle (cm2/m2) |  |  |  < 0.001 |  |  |  < 0.001 |
 Mean ± SD | 37.972 ± 10.292 | 43.418 ± 8.168 |  | 36.200 ± 6.976 | 48.794 ± 6.694 |  |
Tumor length (cm) | Â | Â | 0.086 | Â | Â | 0.894 |
 Mean ± SD | 4.108 ± 1.974 | 4.501 ± 1.817 |  | 4.360 ± 1.848 | 4.389 ± 1.920 |  |
Vessel invasion | Â | Â | 0.989 | Â | Â | 0.928 |
 Negative | 87 (87%) | 177 (86.8%) |  | 151 (87.3%) | 113 (86.3%) |  |
 Positive | 13 (13%) | 27 (13.2%) |  | 22 (12.7%) | 18 (13.7%) |  |
Perineural invasion | Â | Â | 0.155 | Â | Â | 0.301 |
 Negative | 86 (86%) | 160 (78.4%) |  | 144 (83.2%) | 102 (77.9%) |  |
 Positive | 14 (14%) | 44 (21.6%) |  | 29 (16.8%) | 29 (22.1%) |  |
Differentiation | Â | Â | 0.128 | Â | Â | 0.763 |
 Well | 11 (11%) | 33 (16.2%) |  | 26 (15%) | 18 (13.7%) |  |
 Moderate | 64 (64%) | 138 (67.6%) |  | 112 (64.7%) | 90 (68.7%) |  |
 Poor | 25 (25%) | 33 (16.2%) |  | 35 (20.2%) | 23 (17.6%) |  |
Tumor location | Â | Â | 0.232 | Â | Â | 0.568 |
 Upper | 5 (5%) | 4 (1.9%) |  | 17 (9.8%) | 12 (9.2%) |  |
 Middle | 48 (48%) | 112 (54.9%) |  | 95 (54.9%) | 65 (49.6%) |  |
 Lower | 47 (47%) | 88 (43.1%) |  | 61 (35.3%) | 54 (41.2%) |  |
TNM stage | Â | Â | 0.203 | Â | Â | 0.665 |
 I | 28 (28%) | 44 (21.6%) |  | 44 (25.4%) | 28 (21.4%) |  |
 II | 44 (44%) | 83 (40.7%) |  | 72 (41.6%) | 55 (42%) |  |
 III | 28 (28%) | 77 (37.7%) |  | 57 (32.9%) | 48 (36.6%) |  |
Adjuvant treatment | Â | Â | 0.450 | Â | Â | 0.098 |
 No | 75 (75%) | 143 (70.1%) |  | 131 (75.7%) | 87 (66.4%) |  |
 Yes | 25 (25%) | 61 (29.9%) |  | 42 (24.3%) | 44 (33.6%) |  |
Albumin (g/L) | Â | Â | 0.917 | Â | Â | 0.709 |
 Mean ± SD | 40.762 ± 5.526 | 40.695 ± 5.164 |  | 40.816 ± 5.547 | 40.587 ± 4.915 |  |
NPS | Â | Â | 0.602 | Â | Â | 0.829 |
 1 | 23 (23%) | 44 (21.6%) |  | 36 (20.8%) | 31 (23.7%) |  |
 2 | 47 (47%) | 87 (42.6%) |  | 78 (45.1%) | 56 (42.7%) |  |
 3 | 30 (30%) | 73 (35.8%) |  | 59 (34.1%) | 44 (33.6%) |  |
PNI | Â | Â | 0.731 | Â | Â | 0.131 |
 Mean ± SD | 50.872 ± 7.134 | 51.152 ± 5.606 |  | 50.597 ± 6.267 | 51.671 ± 5.937 |  |
COUNT | Â | Â | 0.621 | Â | Â | 0.477 |
 Normal/light | 75 (75%) | 146 (71.6%) |  | 129 (74.6%) | 92 (70.2%) |  |
 Moderate | 25 (25%) | 58 (28.4%) |  | 44 (25.4%) | 39 (29.8%) |  |